Prihlásiť sa Zaregistrujte sa zadarmo

1 ročný cieľ spoločnosti AC Immune SA

Aká je hodnota metriky 1 ročný cieľ spoločnosti AC Immune SA?

Hodnota metriky 1 ročný cieľ spoločnosti AC Immune SA je $12 +275.94%

Aká je definícia metriky 1 ročný cieľ?

1-ročný cieľ (1-year target) je analytikmi predpokladaná cena akcie za rok od dnešného dňa.

One year target is an estimate of a stock price for a point in time equal to a year from the current date. The price level most often reflects the collective opinion of different analysts on where the stock will be trading a year from now. For an analyst to identify an individual estimate, they have to project what a company’s business will look like in a year, typically focusing on revenue and other significant factors. They also consider the willingness of investors to pay a certain price. While the average or median recommendation may be predictive and reflect the actual future value, the results are usually not extremely successful.

1 ročný cieľ spoločností v sektore Health Care sektor na NASDAQ v porovnaní so spoločnosťou AC Immune SA

Čomu sa venuje spoločnosť AC Immune SA?

ac immune is a clinical-stage swiss-based biopharmaceutical company, listed on nasdaq, which aims to become a global leader in precision medicine for neurodegenerative diseases. the company designs, discovers and develops therapeutic as well as diagnostic products intended to prevent and modify diseases caused by misfolding proteins. ac immune’s two proprietary technology platforms create antibodies, small molecules and vaccines designed to address a broad spectrum of neurodegenerative indications, such as alzheimer’s disease (ad). the company’s pipeline features nine therapeutic and three diagnostic product candidates – with five product candidates currently in clinical trials. the most advanced of these is crenezumab, a humanized anti-amyloid-β monoclonal igg4 antibody that targets monomeric and aggregated forms of amyloid-β, with highest affinity for neurotoxic oligomers. crenezumab is currently in two phase 3 clinical studies for ad, under a global program conducted by the collabor

Firmy s metrikou 1 ročný cieľ podobnou spoločnosti AC Immune SA